



Buyback programme

On 19 August 2016, Ambu initiated a parallel share buyback programme for the purpose of hedging share-based incentive programmes.

The share buyback programme is expected to end on 30 September 2016 at the latest and comprise a total share buyback of up to 268,000 B-shares.

Under the share buyback programme, the following transactions were conducted in the period 8 September to 16 September 2016:

Date	Number of B shares	Average market price	Transaction value
Accumulated latest announcement	112,816	328.5	37,064,096
8 September 2016	3,000	341.3	1,023,994
9 September 2016	32,000	334.0	10,689,290
12 September 2016	10,000	320.3	3,202,897
13 September 2016	25,000	323.5	8,087,113
14 September 2016	20,000	320.0	6,399,585
15 September 2016	10,000	321.0	3,209,808
16 September 2016	17,584	324.7	5,709,460
Accumulated under the programme	230,400	327.2	75,386,242

Following the above transactions, Ambu owns a total of 1,327,872 Class B shares with a nominal value of DKK 2.75 each, corresponding to 2.5% of the share capital. The total number of Class A and Class B shares in the company is 48,370,720 including treasury shares.

Contact

Lars Marcher, President & CEO, tel. +45 5136 2490, email: lm@ambu.com

About Ambu

Since 1937, breakthrough ideas have fuelled our work on bringing efficient healthcare solutions to life. This is what we create within our fields of excellence – Anaesthesia, Patient Monitoring & Diagnostics, and Emergency Care. Millions of patients and healthcare professionals worldwide depend on the functionality and performance of our products. We are dedicated to improve patient safety and determined to advance single-use devices. The manifestations of our efforts range from early inventions like the Ambu Bag™ resuscitator and the legendary BlueSensor™ electrodes to our newest landmark solutions like the aScope™ endoscope – the world's first single-use flexible video scope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognized medical companies in the world. Headquartered near Copenhagen in Denmark, Ambu employs approximately 2,300 people in Europe, North America and the Asia Pacific. For more information, please visit www.ambu.com.